

Special Issue

Cardiomyopathy and Precision Medicine: 2nd Edition

Message from the Guest Editor

The diagnosis of the most common forms of cardiomyopathies, have long been based on morphology and function by non-invasive diagnostic modalities. In addition, despite extensive studies on biophysical, cellular, and animal models, the current approaches to the management of patients with cardiomyopathies remain largely unchanged. Recent advances in genetics, proteomics, metabolomics, and microbiomics have broadened our understanding of the molecular and cellular pathophysiology of cardiovascular diseases including cardiomyopathies, which can potentially lead to more precise risk prediction and the discovery of optimal treatment strategies for individual patients. Novel approaches, such as artificial intelligence and machine learning to medical big data from various sources including clinical registries, electronic health records, biomarkers, medical images, and all spectrum of 'omics' data, have huge potential for empowering personalized medicine for cardiomyopathy patients. This Special Issue aims to the current knowledge and future perspectives in the potential analytic approaches leading to personalized medicine for cardiomyopathies.

Guest Editor

Dr. Yuji Nagatomo

Department of Cardiology, National Defense Medical College,
Tokorozawa, Saitama, Japan

Deadline for manuscript submissions

closed (25 December 2024)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/188703

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).